Kennedy Capital Management LLC Raises Position in BioNTech SE (NASDAQ:BNTX)

Kennedy Capital Management LLC boosted its stake in BioNTech SE (NASDAQ:BNTX - Free Report) by 258.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 13,820 shares of the company's stock after purchasing an additional 9,964 shares during the period. Kennedy Capital Management LLC's holdings in BioNTech were worth $1,575,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BNTX. State Street Corp lifted its position in shares of BioNTech by 2.0% during the third quarter. State Street Corp now owns 155,867 shares of the company's stock worth $18,512,000 after purchasing an additional 3,014 shares in the last quarter. Exome Asset Management LLC acquired a new stake in BioNTech during the 3rd quarter worth approximately $4,104,000. GAMMA Investing LLC lifted its holdings in BioNTech by 48.2% during the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company's stock worth $105,000 after buying an additional 300 shares in the last quarter. Retireful LLC purchased a new position in BioNTech in the 4th quarter valued at approximately $260,000. Finally, Atomi Financial Group Inc. grew its stake in shares of BioNTech by 6.7% in the fourth quarter. Atomi Financial Group Inc. now owns 3,635 shares of the company's stock worth $414,000 after acquiring an additional 229 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Stock Performance

BNTX traded up $0.51 during trading on Friday, hitting $98.76. 723,188 shares of the stock were exchanged, compared to its average volume of 855,600. The firm has a market capitalization of $23.70 billion, a P/E ratio of -47.03 and a beta of 1.07. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The stock has a fifty day moving average price of $102.79 and a two-hundred day moving average price of $110.94. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, beating the consensus estimate of $0.38 by $0.70. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech's revenue for the quarter was down 19.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.90 EPS. As a group, sell-side analysts predict that BioNTech SE will post -3.88 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. BMO Capital Markets lifted their target price on BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. Morgan Stanley decreased their price objective on BioNTech from $145.00 to $139.00 and set an "overweight" rating for the company in a research note on Tuesday, March 11th. HC Wainwright cut their target price on shares of BioNTech from $150.00 to $145.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Citigroup started coverage on shares of BioNTech in a research note on Thursday, March 13th. They issued a "buy" rating and a $145.00 price target for the company. Finally, Truist Financial began coverage on shares of BioNTech in a research report on Friday, January 10th. They issued a "buy" rating and a $172.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $143.44.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.